Complex biological modelling leveraging the intersection of mechanistic and AI-based hybrid modelling methodologies.
Mechanistic, quantitative models on a molecular level that are able to explore design spaces of complex products in-silico to inform design decisions
Our pipelines leverage the most advanced high throughput experimental technologies to inform our models.
of clinical trials fail, even though each therapy can take 10-15 years and up to $1Bn to get to market.
per year worth of experimental resource wastage in the USA per year on irreproducible research.
cell and gene therapies currently in development with an annual growth rate of 7%
being invested into new cell and gene therapy startup companies every year
Tumour Micro-Environment (TME)
Status: Prototype Development
Our models guide critical decisions in early development to unlock predictions about the efficacy and safety of potential therapeutics. Our model minimises risk and maximises outcome based on rational integration of all currently available data.
TME - Product Model
Status: Prototype Development
We are building a comprehensive library of models for major nanoparticle technologies that can be adapted to specific client products, including: Oncolytic Viruses, Viral Vectors, LNP/VLP for use alongside our TME model.
Product + pipeline analysis
We conduct a review of the products that our customers would like to test the efficacy for against our simulated TME. We also review their experimental pipeline to see whether additional data would improve results.
Once this data is shared with us, we create specific Product models representing the product that the customers has shared with us. This product model remains the IP of the customer.
We will produce results of running the product(s) against our TME and provide results of the efficacy, safety and any further advice regarding how they may be able to improve the therapy from co-targeting or arming.
Chief executive officer
Experienced founder and product expert, CPO at Cardeo (FinTech), Ex-COO at HeyHub, Ex-Head of Product at CompareTheMarket.
Chief technology officer
Ex-Microsoft Research, Group lead of Biological Modelling at Oxford Biomedica. PhD in Theoretical Physics (LMU Munich)
Chief scientific officer
Director at Post Urban Ventures, Chief Scientist at Hazy and FLOX, NED at Earth Rover, PhD in Physics (University of Cambridge)
Data Science Advisor
Ex-Evaluate NLP Data Scientist, Deep-tech scientist at Post UrbanVentures, PhD Medicine (National University of Singapore)
We work with companies that are developing immunotherapies and are looking to improve outcomes by leveraging the data they possess alongside our TME models.
Partnering with tumour-on-a-chip organisations allows us to share knowledge and information integral for the development of our shared and independent pipelines.
Sharing a systems medicine based view of the TME with developers, allows for effective and efficient knowledge transfer.
We're always happy to have a coffee. You can contact us on firstname.lastname@example.org and someone will get back to you in due course. We're based across the UK but are primarily based in Cambridge, London and Oxford.